The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Five regions in the U.S. have been selected to implement a new preventive health initiative to improve care for people with a cluster of chronic conditions known as cardiovascular-kidney-metabolic ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...

About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, ...

About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, kidney disease, type 2 diabetes and obesity.[1] This cluster of chronic ...

American Heart Association initiative aims to improve care for people in Atlanta; Baton Rouge, La.; Washington, D.C.; Maryland; San Diego and Ohio who have a cluster of conditions called cardiovascula ...

Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as ...